SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June, 2024
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
Description of Exhibits | |
99.1 | Press Release dated June 3, 2024 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
Date: June 03, 2024 | By: | /s/ K Randhir Singh | |
Name: | K Randhir Singh | ||
Title: | Company Secretary |
3
Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
June 3, 2024
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Press Release
Please find enclosed a Press Release on “Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities”. Aurigene Pharmaceutical Services Limited is a step down wholly owned subsidiary of the Company.
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Encl: As above
Press release
Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities
Hyderabad, India- June 03, 2024: Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements. The process and analytical development laboratories are now operational while the commissioning of manufacturing capacity will be completed later in 2024.
The state-of-the-art facility is equipped with best-in-class equipment and control systems, supported by an experienced talent pool that will ensure seamless transfer to large-scale commercial CGMP manufacturing facilities. The new facility is complementary to the company’s current discovery capabilities and infrastructure, which primarily focuses on recombinant proteins including mAbs, bi- and multi-specifics, immune-fusion molecules, antibody drug conjugates and other complex proteins.
Aurigene’s comprehensive end-to-end service offering now delivers solutions from, discovery through large-scale commercial manufacturing from three proximally located campuses (discovery, process development/clinical manufacture and large scale commercial manufacture) thus ensuring seamless delivery from “concept to commercial”. The newly opened Genome Valley facility will deliver robust, compliant and economically viable cell lines, process development solutions and supporting analytical methods in support of customers seeking to rapidly enter and progress through clinical development.
The opening of this latest facility is one of multiple strategic initiatives that Aurigene is implementing to support rapid growth in both the small molecule and biologics spaces, as illustrated by recent announcements related to AI/ML-led drug discovery in small molecules and a collaboration with Vipergen, a DNA-encoded library (DEL) technologies service provider.
Akhil Ravi, CEO, Aurigene, commented, “The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational and the addition of this capacity and capabilities shows our firm commitment to the continued expansion of our biologics business, building on 25 years of proven experience. The state-of-the-art facility will enable us to service our global customers efficiently and support in the development of innovative medicine.”
Dr. Roger Lias, Global Commercial Head – Biologics, Aurigene, added, “There are very few global CDMOs that can truly support customers “end-to-end” from discovery services to large scale commercial manufacture of both Drug Substance and Drug Product. Our new facility further strengthens Aurigene’s capabilities and builds on our technical excellence, demonstrated global compliance and state-of-the-art facilities as companies from start-up biotechs to global multinationals continue to strengthen their supply chains and seek economically viable support for both their development portfolios and marketed products.”
About Aurigene:
Aurigene is a global contract research, development, and manufacturing organization (CRDMO) – a Dr. Reddy’s company - built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of biologics and small molecules. Aurigene offers integrated and standalone services for biotherapeutics discovery, discovery chemistry, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing.
For more information log on to: https://www.aurigeneservices.com/ or email us at: ContactAPSL@aurigeneservices.com LinkedIn YouTube
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.
CONTACTS
Usha Iyer Head of Corporate Communications ushaiyer@drreddys.com |
Richa Periwal Head of Investor Relations richaperiwal@drreddys.com |
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end
M^209LOJ;&::Q&JB$%J [(BLF"PI@2
M_'OV _R!E,KD>1\JY9CL)>R!<1LT4X7)5X1[=7\.R;63$][0;^YYF*+8!?C'
M^G03W-,;8Y1\DT\EQMP1F*G&%9GC=HNP$X;NX%G,3'[5A3"4?^):_;H*XWD%
M;D6#Y;FZRS2%[E7&3.LR-&I<'\
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end